Erschienen in:
12.09.2016 | Nephrology - Original Paper
Application of bioimpedance spectroscopy in Asian dialysis patients (ABISAD-III): a randomized controlled trial for clinical outcomes
verfasst von:
Chen Huan-Sheng, Chang Yeong-Chang, Hsieh Ming-Hsing, Tseng Fan-Lieh, Lin Chu-Cheng, Wu Tsai-Kun, Chen Hung-Ping, Hung Sze-Hung, Chiu Hsien-Chang, Lee Chia-Chen, Hou Chun-Cheng, Cheng Chun-Ting, Liou Hung-Hsiang, Lin Chun-Ju, Lim Paik-Seong
Erschienen in:
International Urology and Nephrology
|
Ausgabe 11/2016
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Fluid management with body composition monitor based on bioimpedance spectroscopy (BCM-BIS) has been found to be beneficial for dialysis patients. We conducted a study to provide an algorithm for the determination of post-dialysis target weight (PDTW) and to evaluate whether this approach could improve clinical outcomes compared to patients who had PDTW decided clinically.
Methods
Two hundred and ninety-eight dialysis patients participated in this 1-year randomized controlled trial. The outcomes were all-cause hospitalization rate, AFO or CV-related events, hypertension and intra-dialysis morbidities.
Results
80 % of post-dialysis weight reached the target set with current algorithm. All-cause hospitalization rate was not different. Incidence of acute fluid overload (AFO) or CV-related events was lower in study group. Longitudinal data showed decreased incidence of hypertension, intra-dialysis morbidities and intra-dialysis hypotension.
Conclusions
Assessment of PDTW by BCM-BIS with an explicit algorithm decreased AFO or CV-related events, hypertension and intra-dialysis morbidities. Further studies were required to demonstrate possible benefits of hospitalization rate.